Today’s BioHealth Business Daily is full of some of the names you might expect to see, but it also has some unusual names as well. We are seeing share price moves in Accuray Incorporated…
Monday is seeing many winners and losers in the healthcare sector on the heels of the health care reform passage in the House of Representatives this weekend. We are focusing solely on the biotech,…
No matter what legislation comes out of the frenzied health care debate, economists say that it will cost the American taxpayer a great deal. Estimates run the gamut from the Obama administration’s claim that it…
This week is a jam-packed list full of the Unusual Suspects. We have many earnings reports, enough that we had to screen out some, and we have many issues to watch for news, charts,…
We are seeing many key movers in the BioHealth space today as drug and biotech stocks often exhibit the most volatility of any sector. Today’s BioHealth Business Daily includes the key moves and news…
These are some of the top movers in the world of BioHealth investing. It is usual that drug companies and biotech stocks have major volatility around news and these are examples of that today. …
After months of bickering, it looked like the Congressional vote on the Obama-esque healthcare reform package was too close to call. Democrats have been questioning members of their own party to vote with them for…
We are seeing many key movers in the BioHealth space today. Biotech stocks and drug stocks are often more volatile than other sectors. Today’s BioHealth Business Daily includes the key moves and news seen…
Virtually nothing has gone right at Boston Scientific (BSX) since it bought rival Guidant in a bidding war with Johnson & Johnson (JNJ) in 2006. With a year of the transaction closing Guidant had to withdraw 50,000 medical…
This week we have several issues to watch. Earnings season is mostly done but there are still many on deck in this week’s unusual suspects. Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN), Eli Lilly & Co.…
Pfizer (PFE) and other big pharma companies have been under assault for several years as some of their most profitable drugs lose patent protection which creates low-priced generic competition. Pfizer has not been able to…
Average: “an estimation of or approximation to an arithmetic mean”–Webster The smartest move that J. Raymond Elliot made in his career was to leave the Boston Scientific (BSX) board in 2009 after less than…
Biophama companies are horrible investments at least 90% of the time because they are gambles on the IQs of small groups of scientists and the whims of the FDA. Poniard Pharmaceuticals (PARD) and Lexicon Pharmaceuticals (LXRX) proved the…
Biotech firm XenoPort (XNPT) will lay-off half of its employees. The company lists 219 full-time workers. On February 17, the FDA rejected a restless leg syndrome drug being developed by XenoPort and GlaxoSmithKline (GSK) because of…
All the US government has to do to pay for the current healthcare reform proposal is eliminate foodborne illnesses like botulism, salmonella, and e-coli. A new study from The Product Safety Project says that “acute foodborne illnesses…